ASCO 2024: Lung Cancer

CME

Conference to Clinic: Expert Analysis of the Top Abstracts in Lung Cancer From the 2024 Oncology Meeting in Chicago

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 23, 2024

Expiration: February 22, 2025

Activity

Progress
1 2
Course Completed

References

  1. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301-1311.
  2. Spigel DR, Cheng Y, Cho BC, et al. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract LBA5.
  3. Faivre-Finn C, Spigel DR, Senan S, et al. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Presented at: European Society of Medical Oncology Congress; October 19- 23, 2018. Abstract 1363O.
  4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small-cell lung cancer v7.2024. nccn.org. Accessed August 12, 2024.
  5. Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389:137-147.
  6. Naidoo J, Antonia S, Wu Y-L, et al. Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC. J Thorac Oncol. 2023;18:657-663.
  7. Shi C, Wang Y, Xue J, et al. Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. Front Immunol. 2022:13:940288.
  8. Ramalingam SS, Kato T, Dong X, et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: primary results of the phase 3 LAURA study. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract LBA4.
  9. Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;[Epub ahead of print].
  10. Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41:1830-1840.
  11. Tsutani Y, Goldman J, Dacic S, et al. Adjuvant osimertinib vs. placebo in completely resected stage 1A2-1A3 EGFR-mutated NSCLC: ADAURA2. Clin Lung Cancer. 2023;24:376-380.
  12. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.
  13. Amivantamab [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2024.
  14. Cho B, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;[Epub ahead of print].
  15. Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35:77-90.
  16. Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract LBA8505.
  17. Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated NSCLC: primary results from the phase 3 PALOMA-3 study. J Clin Oncol. 2024;[Epub ahead of print]. 
  18. Oncology Nursing News. FDA receives BLA seeking approval for subcutaneous amivantamab in EGFR+ NSCLC. oncnursingnews.com/view/fda-receives-bla-seeking-approval-for-subcutaneous-amivantamab-in-egfr-nsclc. Accessed August 12, 2024.
  19. Lim SM, Tan JL, Dias JM, et al. Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): results from the phase 2 PALOMA-2 study. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract LBA8612.
  20. Yang JCH, Doucet L, Wang M, et al. A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: primary analysis of WU-KONG1 study. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract 8513.
  21. Sotorasib [prescribing information]. Thousand Oaks, CA: Amgen; 2024.
  22. Adagrasib [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2024.
  23. Mok TSK, Yao W, Duruisseaux, et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract LBA8509.
  24. De Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2024;401:733-746.
  25. Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract LBA8500.
  26. Ahn M-J, Paz-Arez L, Cornelissen R, et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. Presented at: European Society of Medical Oncology Congress 2023; September 20-24, 2023. Abstract LBA12.
  27. Lisberg A, Ahn MJ, Kitazono S, et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung 05. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract 8593.
  28. Li BT, Planchard D, Goto K, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02. Presented at: European Society of Medical Oncology Congress 2023; September 20-24, 2023. Abstract 1321MO.
  29. Johnson ML, Janne PA, Goto Y, et al. Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01. Presented at: European Society of Medical Oncology Congress 2023; September 20-24, 2023. Abstract 1319MO.
  30. Heymach J, Opdam F, Barve MA, et al. Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract 8514.
  31. Chia PL, John T, Dobrovic A, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014;6:423-432.
  32. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31:1056-1064.
  33. Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16:2091-2108.
  34. Solomon BJ, Bauer T, Mok TS, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023 Apr;11:354-366.
  35. Lorlatinib [prescribing information]. New York, NY: Pfizer; 2023.
  36. Solomon BJ, Geoffrey L, Felip E, et al. Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract LBA8503
  37. Solomon BJ, Geoffrey L, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non–small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol. 2024;[Epub ahead of print].
  38. Dagogo-Jack I and Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol. 2016; 27(Suppl 3):iii42-iii50.
  39. Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023 41:4852-4863.
  40. Janne PA, Goto Y, Kubo T, et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract 8543.
  41. Greer JA, Trotter C, Jackson V, et al. delivered via telehealth versus in person among patients with advanced lung cancer. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract LBA3.
  42. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non–small-cell lung cancer. N Engl J Med. 2010;363:733-742.